The coagulation-anticoagulation protein network is the fundamental system that maintains blood fluidity, localized hemostasis, and vascular integrity. This network is not a simple linear chain composed of several independent coagulation factors, but rather a multi-node coupled structure formed by the procoagulant cascade, natural anticoagulant axes, the fibrinolytic system, platelet adhesion molecules, and endothelial regulatory molecules. In cardiovascular diseases, endothelial injury, abnormal hemodynamics, inflammatory amplification, lipid deposition, and tissue ischemia can collectively drive this network from physiologic spatially restricted hemostasis toward pathologic thrombogenesis, microcirculatory impairment, and organ perfusion imbalance. Therefore, understanding the dynamic remodeling of coagulation and anticoagulant proteins from a network perspective is highly important for elucidating the mechanisms underlying atherosclerosis, acute coronary syndrome, atrial fibrillation, heart failure, venous thromboembolism, and microvascular lesions.
Keywords: cardiovascular disease; coagulation; anticoagulation; thrombin; tissue factor; protein C; antithrombin; tissue factor pathway inhibitor; von Willebrand factor; fibrinolysis
I. Basic Structure of the Coagulation-Anticoagulation Protein Network
1.1 The Coagulation System Is a Multi-Layer Amplification Network
(1) Tissue factor exposure determines the initiation of the procoagulant response
When the vascular endothelium remains intact, circulating coagulation factors are spatially separated from the procoagulant surface of the vessel wall. Upon endothelial injury, plaque rupture, or inflammatory activation, tissue factor exposure or upregulation can rapidly form an initiation complex with coagulation factor VII/VIIa, activate factors IX and X, and drive thrombin generation.
(2) Thrombin is the central amplification node in the network
Thrombin not only converts fibrinogen into fibrin, but also activates factors V, VIII, XI, and XIII, while promoting platelet activation. Therefore, thrombin is not merely a single terminal enzyme, but the key hub that amplifies local signals into a stable thrombotic structure.
1.2 The Natural Anticoagulant System Provides Boundary Control
(1) Natural anticoagulant proteins restrict the spatial spillover of coagulation
Antithrombin, the protein C system, and tissue factor pathway inhibitor together constitute the anticoagulant inhibitory axis. Their core role is not to completely block coagulation, but to confine coagulation reactions to the injured area and prevent unnecessary fibrin deposition in regions of normal blood flow.
(2) The anticoagulant network also participates in endothelial protection and inflammatory buffering
Activated protein C, in addition to degrading factors Va and VIIIa, can reduce inflammatory amplification, maintain barrier stability, and improve microcirculatory perfusion through endothelial-associated signaling. Thus, the anticoagulant system itself possesses dual properties of hemostatic regulation and vascular protection.
1.3 The Fibrinolytic and Platelet Systems Jointly Determine the Final Thrombus Phenotype
(1) The balance between coagulation and fibrinolysis determines whether a thrombus persists
tPA, urokinase-type plasminogen activator, plasmin, and their inhibitors together determine whether a thrombus can be confined and cleared. If fibrinolysis is continuously suppressed, the coagulation network is more likely to evolve into a sustained prothrombotic state.
(2) Platelet adhesion and von Willebrand factor determine initiation efficiency under high shear conditions
Particularly in the arterial system and microcirculation, the platelet-vWF axis is tightly coupled to the coagulation protein network and is a critical prerequisite for rapid thrombus formation after plaque rupture.
II. Core Components and Functional Stratification of the Coagulation Protein Network
2.1 The Initiation Layer Is Dominated by the Tissue Factor Pathway
(1) Tissue factor is the key interface linking inflammation and coagulation
Monocytes, endothelial cells, and smooth muscle cells can all upregulate tissue factor expression under conditions of inflammation, oxidative stress, and plaque instability. Its pathological significance lies in directly converting vascular inflammation into a procoagulant signal.
(2) The factor VIIa-tissue factor complex determines initiation efficiency
This complex can trigger activation of factors IX and X within a short time, thereby creating the prerequisite for a burst of thrombin generation. It therefore functions as the initiation switch in acute thrombus formation.
2.2 The Amplification Layer Is Supported by the Intrinsic Pathway and Cofactor Systems
(1) Factors IXa, VIIIa, and Xa constitute the core amplification module
On the platelet membrane surface, the Tenase and Prothrombinase complexes markedly enhance catalytic efficiency, allowing thrombin generation to shift from low-level initiation into a high-throughput amplification stage.
(2) The activation states of factors V and VIII determine the threshold for thrombin generation
These cofactors do not themselves possess protease activity, but they are decisive for complex assembly and reaction rate, making them key amplifiers within the coagulation network.
2.3 The Terminal Layer Centers on Thrombin and Fibrin Formation
(1) Thrombin determines the transition of thrombosis from formation to stabilization
Thrombin promotes fibrinogen cleavage and the generation of fibrin monomers, while simultaneously activating factor XIII, which crosslinks fibrin and forms a thrombus scaffold with higher mechanical stability.
(2) Abnormalities at the terminal layer directly determine the risks of embolism and perfusion impairment
If thrombin generation is excessive, fibrin crosslinking is enhanced, and fibrinolysis is suppressed, coronary occlusion, mural cardiac thrombosis, venous thrombosis, and microthrombus formation become more likely.
Table 1. Key Proteins in the Coagulation-Anticoagulation Network in Cardiovascular Diseases and Their Functional Positioning
Protein | System | Main Function | Significance in Cardiovascular Diseases |
Tissue factor (TF) | Coagulation initiation | Initiates the extrinsic coagulation pathway | Links inflammation, plaque rupture, and acute thrombosis |
Factor VIIa | Coagulation initiation | Forms the initiation complex with TF | Determines the intensity of procoagulant initiation |
Factors IXa/VIIIa | Coagulation amplification | Promote factor X activation | Enhance thrombin generation |
Factors Xa/Va | Coagulation amplification | Catalyze the conversion of prothrombin | Drive burst-like thrombin generation |
Thrombin | Terminal effector | Generates fibrin and activates multiple coagulation factors | Core node of thrombus stabilization and network amplification |
Fibrinogen | Terminal substrate | Forms the fibrin scaffold | Determines the structural basis of the thrombus |
Antithrombin | Natural anticoagulation | Inhibits thrombin and factor Xa, among others | Restricts coagulation spillover |
Protein C/Protein S | Natural anticoagulation | Inactivate factors Va and VIIIa | Maintain coagulation and endothelial homeostasis |
TFPI | Natural anticoagulation | Inhibits the TF-VIIa-Xa complex | Restricts excessive coagulation initiation |
vWF | Platelet adhesion | Promotes platelet adhesion under high shear | Key factor in arterial thrombosis and microthrombus formation |
tPA | Fibrinolysis | Activates plasminogen | Promotes thrombus clearance |
PAI-1 | Fibrinolysis inhibition | Inhibits tPA/uPA | Sustains a prothrombotic state |
III. Regulatory Logic of the Natural Anticoagulant Network
3.1 The Antithrombin System Is the Principal Fluid-Phase Inhibitory Axis
(1) Antithrombin mainly inhibits the serine protease cascade
Its targets include thrombin, factors Xa, IXa, and XIa, and it therefore serves as a broad-spectrum brake in the circulating phase.
(2) Its function is regulated by heparan sulfate-like molecules on the endothelial surface
Endothelial glycosaminoglycans can enhance antithrombin activity, indicating that endothelial injury not only raises procoagulant signaling but also simultaneously reduces anticoagulant amplification capacity.
3.2 The Protein C System Is the Core Membrane-Surface Regulatory Module
(1) Thrombomodulin determines the functional direction of thrombin
When thrombin binds thrombomodulin, its substrate preference shifts from procoagulant activity toward protein C activation. This transition reflects the functional plasticity of the same protease in different microenvironments.
(2) Activated protein C exerts both anticoagulant and cytoprotective effects
In addition to inhibiting factors Va and VIIIa, it also participates in reducing endothelial inflammation, lowering permeability, and buffering microcirculatory injury. For this reason, it is particularly relevant in septic myocardial suppression, ischemia-reperfusion, and microvascular dysfunction.
3.3 TFPI Restrains Excessive Initiation
(1) TFPI targets the most upstream coagulation events
By inhibiting the TF-VIIa-Xa complex, it reduces initiation cascade amplification after tissue factor triggering.
(2) This mechanism is particularly important for early restriction after plaque rupture
Under conditions of high tissue factor exposure, whether TFPI can provide sufficient early braking directly influences the transition between local hemostasis and pathological occlusion.
IV. Manifestations of the Coagulation-Anticoagulation Network in Major Cardiovascular Pathologies
4.1 Atherosclerosis and Acute Coronary Syndrome
(1) Plaque rupture instantaneously transforms an inflammatory lesion into a procoagulant platform
Exposure of the lipid core, release of tissue factor, collagen exposure, and platelet adhesion collectively trigger acute thrombus formation under high shear conditions.
(2) Coronary events are not simply a platelet problem
Although platelets are highly important in arterial thrombosis, thrombin generation, fibrin deposition, and fibrinolytic suppression also determine the speed and duration of occlusion.
4.2 Atrial Fibrillation and Intracardiac Thrombus Formation
(1) Blood stasis, endothelial abnormality, and a procoagulant state all participate
Atrial fibrillation causes reduced local flow velocity in the left atrial appendage and is accompanied by endothelial dysfunction and coagulation activation, making the anticoagulant network insufficient to fully offset local prothrombotic signals.
(2) The essence of anticoagulant therapy is the restoration of network balance
It does not simply reduce blood viscosity, but suppresses local procoagulant amplification by inhibiting factor Xa or thrombin.
4.3 Heart Failure and the Microcirculatory Prothrombotic State
(1) Heart failure is often accompanied by low-grade inflammation and endothelial activation
This elevates tissue factor, vWF, PAI-1, and related factors, shifting the balance between coagulation and fibrinolysis toward thrombosis.
(2) Its clinical problem is not limited to large thrombi
Reduced microcirculatory perfusion, local fibrin deposition, and endothelial injury can further aggravate organ hypoperfusion and myocardial remodeling.
4.4 Venous Thromboembolism and Hypercoagulable States
(1) The venous system more strongly reflects imbalance in the coagulation protein network
Compared with arterial thrombosis, venous thrombosis more prominently involves sustained amplification of the thrombin-fibrin axis.
(2) Deficiency or consumption of anticoagulant proteins can markedly increase risk
When protein C, protein S, or antithrombin function is insufficient, the threshold for venous thrombosis is significantly lowered.
V. Cross-Coupling of the Coagulation-Inflammation-Endothelium Network
5.1 Coagulation Proteins Can Reciprocally Drive Inflammation
(1) Thrombin can mediate cellular signaling through PAR receptors
It not only generates fibrin, but also activates endothelial cells, smooth muscle cells, and immune cells, promoting inflammatory factor expression and changes in vascular reactivity.
(2) Fibrin itself can also become a component of the inflammatory microenvironment
Its deposition can alter leukocyte adhesion, tissue repair, and matrix remodeling, thereby prolonging the duration of injury responses.
5.2 Inflammation Can Continuously Weaken Anticoagulant Protection
(1) Under inflammatory conditions, the endothelial anticoagulant phenotype declines
When thrombomodulin, endothelial protein C receptor, and heparan sulfate-like molecules are downregulated, both the protein C system and antithrombin-enhancing mechanisms are impaired.
(2) This makes procoagulant responses more likely to form positive feedback loops
Enhanced coagulation causes more endothelial injury and inflammation, while inflammation further weakens anticoagulation and fibrinolysis, thereby forming a sustained pathological network.
VI. Key Pathways, Targets, and Evaluation Indices in Research and Translation
6.1 Major Research Pathways
(1) TF-VIIa-Xa-thrombin axis
Used to analyze procoagulant initiation, thrombin generation, and fibrin formation efficiency.
(2) Protein C-Protein S-thrombomodulin axis
Used to analyze natural anticoagulant regulation and endothelial protective capacity.
(3) vWF-platelet-high-shear adhesion axis
Used to analyze the initiation mechanisms of arterial and microcirculatory thrombosis.
(4) tPA-plasmin-PAI-1 axis
Used to analyze thrombus clearance capacity and fibrinolytic inhibition status.
6.2 Key Targets
(1) Procoagulant targets
These include tissue factor, factor Xa, thrombin, vWF, and PAI-1.
(2) Anticoagulant targets
These include antithrombin, protein C, protein S, TFPI, and thrombomodulin.
(3) Cross-regulatory targets
These include PAR receptors, endothelial protein C receptor, and inflammation-related endothelial activation molecules.
6.3 Commonly Used Evaluation Indices
(1) Basic coagulation function indices
① Prothrombin time
This mainly reflects the functional state of the extrinsic coagulation pathway and the common pathway, and is one of the most basic indices for assessing overall procoagulant or anticoagulant shifts.
② Activated partial thromboplastin time
This mainly reflects the functional state of the intrinsic coagulation pathway and the common pathway, and is suitable for evaluating abnormalities in coagulation amplification systems.
③ Fibrinogen
This is both the terminal substrate of coagulation and an acute-phase reactant. Its elevation usually indicates an enhanced prothrombotic background.
④ D-dimer
This reflects the consequence of in vivo fibrin formation and degradation and is commonly used to assess whether thrombus formation and fibrinolytic activation are present.
(2) Natural anticoagulant function indices
① Antithrombin
Used to evaluate whether natural fluid-phase anticoagulant capacity is reduced and serves as a basic indicator in hypercoagulability research.
② Protein C
Used to evaluate whether the protein C anticoagulant system is impaired and is suitable for analyzing changes in endothelial protection and anticoagulant balance.
③ Protein S
As an important cofactor of protein C, changes in protein S help determine whether the natural anticoagulant network remains intact.
(3) Platelet- and endothelium-related indices
① von Willebrand factor
Used to reflect platelet adhesion capacity and endothelial activation under high shear conditions and is commonly used in arterial thrombosis research.
② P-selectin
Used to evaluate platelet activation and endothelial adhesive phenotypes and is suitable for observing the extent of thrombosis-inflammation coupling.
(4) Fibrinolytic function indices
① tPA
Reflects fibrinolytic activation capacity and is an important indicator for evaluating thrombus clearance potential.
② PAI-1
Reflects fibrinolytic inhibitory strength, and its elevation generally indicates that a prothrombotic state is more likely to persist.
VII. Commonly Used Products for Related Research
7.1 Screening Table of Coagulation Factors and Related Detection Kits
Catalog No. | Product Name | Grade and Purity | Corresponding Functional Axis/Target | Suitable Research Direction/Application |
Human Coagulation Factor II(FII) ELISA Kit | BioReagent | Prothrombin-terminal procoagulant axis | Suitable for evaluating substrate reserve in the common pathway and precursor status before thrombin generation | |
Recombinant Human Coagulation Factor II/Prothrombin Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,His Tag,≥95%(SDS-PAGE),See COA | Prothrombin-terminal procoagulant axis | Suitable for constructing recombinant prothrombin systems and studying common pathway activation | |
Recombinant Human Coagulation Factor II/Thrombin Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,High Performance,His Tag,≥95%(SDS-PAGE) | Thrombin terminal effector axis | Suitable for recombinant thrombin systems, fibrin formation, and PAR signaling studies | |
Recombinant Human Coagulation Factor II/Thrombin Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,High Performance,≥95%(SDS-PAGE),See COA | Thrombin terminal effector axis | Suitable for establishing highly consistent recombinant thrombin models and studying terminal procoagulant readouts | |
Thrombin | Bioactive,ActiBioPure™,Native,High Performance,EnzymoPure™,from human plasma; 400-1000 NIH U/mg protein | Thrombin terminal effector axis | Suitable for constructing fibrin formation, PAR receptor activation, and endothelial response models | |
Human Coagulation Factor V (FV) ELISA Kit | BioReagent | FV amplification cofactor axis | Suitable for analyzing procoagulant amplification complex assembly efficiency and hypercoagulable backgrounds | |
Human Coagulation Factor VII (FVII) ELISA Kit | BioReagent | FVII initiation-layer procoagulant axis | Suitable for analyzing baseline extrinsic coagulation pathway status and tissue factor responsiveness | |
Human Activated Coagulation Factor VIIa(FVIIa) ELISA Kit | BioReagent | FVIIa initiation complex axis | Suitable for studying the procoagulant initiation intensity driven by the TF-FVIIa complex | |
Human Factor VIIa | FVIIa initiation complex axis | Suitable for constructing in vitro tissue factor initiation models and mechanistic studies of the extrinsic coagulation pathway | ||
Human Coagulation Factor VIII (FVIII) ELISA Kit | BioReagent | FVIII intrinsic amplification axis | Suitable for analyzing Tenase complex efficiency and coagulation amplification capacity | |
Recombinant Human Factor VIII Protein | Carrier Free,His Tag,≥95%(SDS-PAGE),See COA | FVIII intrinsic amplification axis | Suitable for constructing recombinant intrinsic amplification systems and FVIII functional validation | |
Human Coagulation Factor IX(FIX) ELISA Kit | BioReagent | FIX intrinsic amplification axis | Suitable for evaluating intrinsic coagulation pathway activation and sustained procoagulant potential | |
Recombinant Human Coagulation Factor IX Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,His Tag,Fc tag,≥95%(SDS-PAGE) | FIX intrinsic amplification axis | Suitable for constructing recombinant FIX amplification systems and studying intrinsic pathway mechanisms | |
Human Coagulation Factor X (F10) ELISA Kit | BioReagent | FX/Xa common pathway axis | Suitable for analyzing common pathway amplification potential and changes before and after Xa-targeted intervention | |
Factor Xa | 9002-05-5 | Factor Xa amplification axis | Suitable for constructing in vitro procoagulant amplification models and Xa-targeted inhibition studies | |
Recombinant Human Coagulation Factor Xa Protein | Animal Free,Carrier Free,His Tag,≥95%(SDS-PAGE),See COA | Factor Xa amplification axis | Suitable for constructing recombinant Xa systems and evaluating anti-Xa drug effects | |
Human Coagulation Factor XI (FXI) ELISA Kit | BioReagent | FXI intrinsic amplification axis | Suitable for evaluating contact activation and sustained procoagulant amplification backgrounds | |
Human Coagulation Factor XIa(FXIa) ELISA Kit | BioReagent | FXIa activated amplification axis | Suitable for analyzing intrinsic pathway activation degree and the procoagulant enhancement stage | |
Human Factor XIa | FXIa activated amplification axis | Suitable for constructing in vitro intrinsic pathway amplification models and factor inhibition research | ||
Human Coagulation Factor XII(FXII) ELISA Kit | BioReagent | FXII contact activation axis | Suitable for studying contact system-mediated procoagulant initiation and inflammation coupling | |
Human Factor XIIa Beta | FXIIa contact activation axis | Suitable for constructing contact activation models and studying intrinsic procoagulant initiation | ||
Rat Coagulation Factor II(FII) ELISA Kit | BioReagent | Prothrombin-terminal procoagulant axis | Suitable for rat thrombosis and organ perfusion impairment models | |
Rat Coagulation Factor V (F5) ELISA Kit | BioReagent | FV amplification cofactor axis | Suitable for analysis of coagulation amplification and hypercoagulability in rats | |
Rat Coagulation Factor VII(FVII) ELISA Kit | BioReagent | FVII initiation-layer procoagulant axis | Suitable for rat extrinsic coagulation pathway studies | |
Rat Coagulation Factor IX (FIX) ELISA Kit | BioReagent | FIX intrinsic amplification axis | Suitable for rat intrinsic procoagulant amplification studies | |
Rat Coagulation Factor X (FX) ELISA Kit | BioReagent | FX/Xa common pathway axis | Suitable for rat common pathway research and Xa-related intervention assessment | |
Rat Coagulation Factor XI (FXI) ELISA Kit | BioReagent | FXI intrinsic amplification axis | Suitable for rat contact activation and hypercoagulable background studies | |
Rat Coagulation Factor XII (F12) ELISA Kit | BioReagent | FXII contact activation axis | Suitable for rat contact system and inflammation-promoted coagulation studies | |
Mouse Coagulation Factor II(FII) ELISA Kit | BioReagent | Prothrombin-terminal procoagulant axis | Suitable for mouse thrombosis formation and terminal coagulation stage studies | |
Mouse Coagulation Factor V (F5) ELISA Kit | BioReagent | FV amplification cofactor axis | Suitable for research on procoagulant complex formation efficiency in mice | |
Mouse Coagulation Factor VII(FVII) ELISA Kit | BioReagent | FVII initiation-layer procoagulant axis | Suitable for mouse tissue factor initiation pathway studies | |
Mouse Coagulation Factor VIII(F8) ELISA Kit | BioReagent | FVIII intrinsic amplification axis | Suitable for studies of the mouse Tenase amplification system | |
Mouse Coagulation Factor IX (FIX) ELISA Kit | BioReagent | FIX intrinsic amplification axis | Suitable for assessment of intrinsic procoagulant amplification in mice | |
Mouse Coagulation Factor X (F10) ELISA Kit | BioReagent | FX/Xa common pathway axis | Suitable for studies of the mouse common pathway and Xa-targeted interventions | |
Mouse Coagulation Factor XI (FXI) ELISA Kit | BioReagent | FXI intrinsic amplification axis | Suitable for mouse hypercoagulability and contact activation studies | |
Mouse Coagulation Factor XII (FXII) ELISA Kit | BioReagent | FXII contact activation axis | Suitable for mouse contact system and inflammation coupling studies | |
Human Prothrombin Fragment 1+2 (F1+2) ELISA Kit | BioReagent | Indirect thrombin generation readout | Suitable for assessing in vivo prothrombin activation levels and whether procoagulant amplification has been initiated | |
Human Thrombin/antithrombin Complex(TAT) ELISA Kit | BioReagent | Integrated coagulation activation readout | Suitable for analyzing occult hypercoagulability and the degree of coagulation activation | |
Human Thrombin ELISA Kit | BioReagent | Thrombin terminal effector axis | Suitable for quantitative detection of thrombin in human samples and evaluation of network activation |
7.2 Screening Table of Products for Natural Anticoagulation and Endothelial Protection Research
Catalog No. | Product Name | Grade and Purity | Corresponding Functional Axis/Target | Suitable Research Direction/Application |
Antithrombin III from Human Plasma | BioReagent, Native, ≥95%(SDS-PAGE), Pre-lyophilization Protein Concentration | Antithrombin fluid-phase anticoagulant axis | Suitable for constructing natural anticoagulant functional models and studying heparin synergy | |
Human Antithrombin III(AT-III) ELISA Kit | BioReagent | Antithrombin fluid-phase anticoagulant axis | Suitable for analyzing whether natural anticoagulant reserve is reduced under hypercoagulable conditions | |
Human Protein C (PC) ELISA Kit | BioReagent | Protein C anticoagulant protective axis | Suitable for evaluating whether the protein C system is impaired and its relationship with endothelial protection | |
Recombinant Human Coagulation Factor XIV/Protein C Protein | Animal Free,Carrier Free,His Tag,≥90%(SDS-PAGE),See COA | Protein C anticoagulant protective axis | Suitable for constructing recombinant protein C systems and studying natural anticoagulant mechanisms | |
Rat Protein C (PROC) ELISA Kit | BioReagent | Protein C anticoagulant protective axis | Suitable for rat thrombosis, ischemia-reperfusion, and microcirculatory injury models | |
Mouse Protein C (PROC) ELISA Kit | BioReagent | Protein C anticoagulant protective axis | Suitable for mouse prothrombotic and organ perfusion impairment models | |
Human Tissue Factor Pathway Inhibitor (TFPI) ELISA Kit | BioReagent | TFPI initiation inhibition axis | Suitable for analyzing whether tissue factor initiation lacks sufficient restraint | |
Human TFPI ELISA Kit | BioReagent | TFPI initiation inhibition axis | Suitable for quantitative detection of TFPI in human samples and research on limiting procoagulant initiation | |
Mouse Tissue Factor Pathway Inhibitor (TFPI) ELISA Kit | BioReagent | TFPI initiation inhibition axis | Suitable for mouse inflammation-promoted coagulation and local hemostatic restriction studies | |
Human Endothelial Protein C receptor (EPCR) ELISA Kit | BioReagent | EPCR-protein C membrane-surface protective axis | Suitable for analyzing whether the protective output of the protein C system on the endothelial surface is weakened | |
Human Solubility Endothelial Protein C Receptor (sEPCR) ELISA Kit | BioReagent | sEPCR endothelial protection readout | Suitable for evaluating endothelial protective disruption and the degree of protein C system imbalance | |
Human Thrombomodulin (TM) ELISA Kit | BioReagent | Thrombomodulin-protein C activation axis | Suitable for assessing whether the endothelial anticoagulant phenotype has declined | |
Human THBD ELISA Kit | BioReagent | Thrombomodulin-protein C activation axis | Suitable for THBD level monitoring and endothelial anticoagulant function evaluation | |
Human Thrombomodulin/ Soluble (sTM) ELISA Kit | BioReagent | sTM endothelial injury and anticoagulant readout | Suitable for analyzing the loss of anticoagulant protection associated with endothelial injury | |
Rat Thrombomodulin (TM) ELISA Kit | BioReagent | Thrombomodulin-protein C activation axis | Suitable for rat endothelial injury and cardiovascular remodeling studies | |
Mouse Thrombomodulin (TM) ELISA Kit | BioReagent | Thrombomodulin-protein C activation axis | Suitable for mouse prothrombotic and endothelial protection imbalance models | |
Heparin sodium salt | Moligand™, 2mM in Water | Heparin-antithrombin enhancement axis | Suitable for constructing classical anticoagulant systems and in vitro anticoagulant intervention studies | |
Heparin sodium salt | Moligand™, ≥180(units/mg) | Heparin-antithrombin enhancement axis | Suitable for functional anticoagulant models and enzymology research | |
Heparin sodium salt | Moligand™, ≥180 USP units/mg | Heparin-antithrombin enhancement axis | Suitable for standardized anticoagulant function studies | |
Enoxaparin sodium | PharmPure™, USP | Low-molecular-weight heparin anticoagulant axis | Suitable for simulating clinical anticoagulant intervention and Xa inhibition-related studies | |
Rivaroxaban | Moligand™, ≥99% | Factor Xa inhibition axis | Suitable for Xa-targeted intervention studies in atrial fibrillation, venous thrombosis, and hypercoagulable states | |
Apixaban | Moligand™, ≥99% | Factor Xa inhibition axis | Suitable for direct oral anticoagulant-related mechanistic studies | |
Dabigatran Etexilate | Moligand™, ≥98% | Thrombin inhibition axis | Suitable for analyzing the effects of direct thrombin inhibition on thrombosis formation and inflammation coupling |
7.3 Screening Table of Products for Platelet Adhesion and Fibrinolytic System Research
Catalog No. | Product Name | Grade and Purity | Corresponding Functional Axis/Target | Suitable Research Direction/Application |
Human Von Willebrand Factor (vWF) ELISA Kit | BioReagent | vWF-platelet adhesion axis | Suitable for studies of platelet adhesion under high shear conditions and arterial thrombosis tendency | |
Rat Von Willebrand Factor (vWF) ELISA Kit | BioReagent | vWF-platelet adhesion axis | Suitable for rat vascular injury and microthrombus models | |
Mouse Vascular Pseudohemophilic Factor Antigen (VWF Ag) ELISA Kit | BioReagent | vWF antigen axis | Suitable for evaluation of high-shear adhesion and endothelial activation in mice | |
Mouse Von Willebrand Factor (vWF) ELISA Kit | BioReagent | vWF-platelet adhesion axis | Suitable for mouse arterial injury and microcirculatory prothrombotic studies | |
Human Von Willebrand Factor Cleaving Protease (vWFCP) ELISA Kit | BioReagent | ADAMTS13/vWF cleavage axis | Suitable for analyzing whether excessively strong vWF adhesion lacks effective cleavage regulation | |
Human Metallopeptidase Contains Platelet Reactive Protein 13 (ADAMTS13) ELISA Kit | BioReagent | ADAMTS13-vWF balance axis | Suitable for studies of microthrombosis and prothrombotic high-shear backgrounds | |
Mouse Von Willebrand Factor Cleaving Protease (ADAMTS13) ELISA Kit | BioReagent | ADAMTS13-vWF balance axis | Suitable for mouse microvascular lesions and thrombotic tendency studies | |
KF 38789 | ≥97% (HPLC) | P-selectin adhesion axis | Suitable for research on platelet-endothelial adhesion and prothrombotic inflammation coupling | |
Human P-Selectin GlycoProtein Ligand 1 (PSGL1) ELISA Kit | BioReagent | P-selectin-PSGL1 adhesion axis | Suitable for analysis of leukocyte, platelet, and endothelial adhesion networks | |
Human Plasminogen Activator Inhibitor 1 (PAI-1) ELISA Kit | BioReagent | PAI-1 fibrinolysis inhibition axis | Suitable for evaluating persistent prothrombotic states and the degree of fibrinolytic suppression | |
Rat Plasminogen Activator Inhibitor 1 (PAI-1) ELISA Kit | BioReagent | PAI-1 fibrinolysis inhibition axis | Suitable for rat heart failure and inflammation-associated prothrombotic models | |
Mouse Plasminogen Activator Inhibitor 1 (PAI-1) ELISA Kit | BioReagent | PAI-1 fibrinolysis inhibition axis | Suitable for mouse prothrombotic and microcirculatory dysfunction studies | |
Human Type 1 Tissue Plasminogen Activator Inhibitor (tPAI-1) ELISA Kit | BioReagent | tPA-PAI-1 counterbalance axis | Suitable for evaluating the strength of fibrinolytic suppression and hypercoagulable cardiovascular backgrounds | |
Human Plasminogen Activator, Tissue (tPA) ELISA Kit | BioReagent | tPA fibrinolytic activation axis | Suitable for assessing thrombus clearance potential and endothelial release capacity | |
Recombinant Human tissue-typeplasminogen activator for TNK mutant (rhTNK-tPA) ELISA Kit | BioReagent | TNK-tPA fibrinolytic intervention axis | Suitable for thrombolytic drug-related research and detection of engineered tPA variants |
The coagulation-anticoagulation protein network in cardiovascular diseases is not merely an extension of the hemostatic system, but a systemic regulatory network connecting hemodynamic abnormalities, endothelial injury, inflammatory amplification, and organ perfusion dysfunction. What truly determines the disease phenotype is not the isolated increase or decrease of a single coagulation factor, but the dynamic imbalance among multiple subsystems, including procoagulation, anticoagulation, fibrinolysis, and platelet adhesion. Therefore, research on this network should always be based on the continuous logic of initiation, amplification, restriction, and clearance, so as to more accurately understand thrombotic risk, tissue injury, and therapeutic targets in cardiovascular diseases.
For more related articles, please see below: